Hiroaki Okushin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUNDS & AIMS We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus genotype 1b infection. METHODS This is a nationwide multicenter study conducted by the(More)
  • 1